This medication requires a valid prescription. Please refer to the ‘Prescription Guide’ for details.
Note: We can assist only if the medicine is unavailable in your country.”
Shipping:
Room Temperature Shipping
Jemperli (dostarlimab) is shipped under standard conditions, maintaining a consistent room temperature of 15°C to 25°C during transit to ensure product stability and safety.
Disease Indications:
• Endometrial Cancer (advanced or recurrent)
• Recurrent or Advanced Solid Tumors
Manufacturer:
GlaxoSmithKline
Usage:
Intravenous
Jemperli (dostarlimab)
General Description:
Jemperli (dostarlimab) is a prescription intravenous therapy used to treat specific types of advanced or recurrent cancers. It is indicated for adults with certain endometrial cancers (cancer of the womb) and select recurrent or advanced solid tumors. Jemperli works by targeting immune checkpoints, helping the body’s immune system recognize and attack cancer cells to slow disease progression.
Jemperli is administered intravenously under the supervision of a healthcare professional, with dosing schedules determined by your oncologist based on your individual treatment plan.
Getting Jemperli (dostarlimab) in India
Jemperli is approved in the United States and European Union for the treatment of advanced endometrial and select solid tumors. While not yet widely available in India, eligible patients may access Jemperli through a Named Patient Program (NPP) under the guidance of a qualified physician.
MitoGENE assists Indian patients in obtaining Jemperli safely and compliantly, handling all necessary documentation, import approvals, and logistics according to India’s regulatory framework.
If you or a loved one has advanced or recurrent endometrial cancer or solid tumors, MitoGENE ensures a secure, patient-centric process to access Jemperli (dostarlimab). Our services include expert guidance on eligibility, documentation, import approvals, and coordinated delivery, ensuring safe and timely access to this important therapy.
Medicine Approved By:
• Food and Drug Administration (FDA)
• European Medicines Agency (EMA)
Available Dosage Form & Package:
• Single-dose vial: 500 mg/10 mL (50 mg/mL)
How to Access Jemperli (dostarlimab) in India in 4 Simple Steps with MitoGENE via the Named Patient Program (NPP)?
If Jemperli (dostarlimab) is not yet approved or commercially available in India, MitoGENE can assist you in accessing it legally through the Named Patient Program (NPP). Here’s how the process works:
